Ipsen Sa S/Adr (IPSEY) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello and welcome to Ibsen's conference call and webcast for the first quarter 2025 results. I'll now hand you over to David Lowe, Ibsen's CEO. Thank you and hello everyone. I'm delighted to welcome you to our Q1 sales presentation this afternoon, which can also be found on Ibsen.com. Please turn to slide two. Please take note of our forward-looking statements, which outline the routine risks and uncertainties contained within this presentation. Also, any of my commentary on growth will be based on constant exchange rates. Please turn to slide three. I'm going to take you through our sales performance of the first quarter and provide you with a business update after which our CFO, Emmerich Le Chatelier, will join me for the question and answer session. Let's begin by looking at today's highlights. Please turn to slide four. We continued to deliver a strong top-line growth in quarter one. Total sales grew by 11.6%, driven by all three therapeutic areas, and including an increase in contribution from my Corvo and Bill Bay. Since the beginning of the year, we have made good progress with our pipeline, including the EMA regulatory submission of tovorafenib for pediatric low-grade glioma, the entry in phase one of a third-generation RAF inhibitor, complementing our ERK inhibitor with both being in the clinic. On the financing side, we announced in March a successful refinancing of 2 billion, including a 500 billion rated public bond supported by investment grade ratings from Standard & Poor's and Moody's. This provides long-term funding of the firepower for our external innovation strategy. Looking ahead, 2025 promises to be another exciting year for our pipeline with several key milestones, including the expected decision from the EMA for cabometrics in neuroendocrine tu...